title: Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease.
abstract: Although proteolytic processing of pro-von Willebrand factor (pro-vWF) resulting in free propeptide and mature vWF is known to be initiated intracellularly, vWF released from endothelial cells may contain a high proportion of incompletely processed pro-vWF. Because pro-vWF is only rarely detectable in normal human plasma, we investigated whether extracellular processing of pro-vWF is possible. A recombinant preparation (rpvWF) containing both pro-vWF and mature vWF subunits was infused into 2 pigs and 1 dog with severe von Willebrand disease, 2 mice with a targeted disruption of the vWF gene, and 2 healthy baboons. Total vWF antigen (vWF:Ag), free propeptide, and pro-vWF were measured using enzyme-linked immunosorbent assay techniques in blood samples drawn before and after infusion. vWF:Ag increased promptly. No pro-vWF could be detected when the first postinfusion sample was drawn after 30 minutes (pigs) or 60 minutes (mice), but pro-vWF was detectable for short periods when postinfusion samples were drawn after 15 minutes (dog) or 5 minutes (baboons). In contrast, free propeptide was increased at the first timepoint measured, suggesting that it was generated from the pro-vWF in the rpvWF preparation. vWF multimers were analyzed in the rpvWF preparation and in plasma samples drawn before and after infusion of rpvWF using ultra-high resolution 3% agarose gels to allow separation of homo- and hetero-forms of the vWF polymers. Within 30 minutes after infusion in the pigs, 1 hour in the dog and the mice, and within 2 hours in the baboons, the multimer pattern had changed to that typically seen in mature vWF. These data indicate that propeptide cleavage from unprocessed vWF can occur extracellularly in the circulation. The enzyme or enzymes responsible for this cleavage in plasma remain to be identified.
authors.affiliation: Baxter Hyland Immuno, Vienna, Austria.
authors.forename: P L
authors.initials: PL
authors.lastname: Turecek
authors.forename: L
authors.initials: L
authors.lastname: Pichler
authors.forename: W
authors.initials: W
authors.lastname: Auer
authors.forename: G
authors.initials: G
authors.lastname: Eder
authors.forename: K
authors.initials: K
authors.lastname: Varadi
authors.forename: A
authors.initials: A
authors.lastname: Mitterer
authors.forename: W
authors.initials: W
authors.lastname: Mundt
authors.forename: U
authors.initials: U
authors.lastname: Schlokat
authors.forename: F
authors.initials: F
authors.lastname: Dorner
authors.forename: L O
authors.initials: LO
authors.lastname: Drouet
authors.forename: J
authors.initials: J
authors.lastname: Roussi
authors.forename: J A
authors.initials: JA
authors.lastname: van Mourik
authors.forename: H P
authors.initials: HP
authors.lastname: Schwarz
mesh_terms: D000818:Animals; D004285:Dogs; D006801:Humans; D051379:Mice; D011498:Protein Precursors / Q000008:administration & dosage / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood; D013552:Swine; D014842:von Willebrand Diseases / Q000188:drug therapy / Q000378:metabolism*; D014841:von Willebrand Factor / Q000008:administration & dosage / Q000378:metabolism*
chemical_list: D011498:Protein Precursors; D011994:Recombinant Proteins; D014841:von Willebrand Factor; C067003:von Willebrand factor propolypeptide